Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-99245354 (ITI-1284) as Adjunctive Treatment in Generalized Anxiety Disorder
NCT07856420Phase 3Recruiting
- Sponsor
- Intra-Cellular Therapies
- Start
- Sep 2026
- Primary completion
- Sep 2030
- Countries
- 1
01
Overview
A Phase 3 trial of deulumateperone in generalized anxiety disorder (GAD), sponsored by Intra-Cellular Therapies. Started Sep 2026; status: recruiting.
02
Drugs
deulumateperone
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT07856420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07856420.